title: An overview of ondansetron for chemotherapy-induced nausea and emesis.
abstract: Nausea and vomiting are major complications associated with the administration of cytotoxic drugs. Ondansetron (Zofran, Glaxo, Inc., Research Triangle Park, NC), a 5-hydroxy tryptamine (5-HT3) serotonin antagonist, has shown efficacy in managing chemotherapy-induced nausea and vomiting without extrapyramidal side effects. The author provides an overview of recent studies and manufacturer's administration recommendations, as well as guidelines for nursing care and patient teaching.
authors: F
authors: F
authors: San Angel
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy* / Q000451:nursing; D017294:Ondansetron / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy* / Q000451:nursing
chemical_list: D000970:Antineoplastic Agents; D017294:Ondansetron